Moxifloxacin: Clinically compatible contrast agent for multiphoton imaging
Name
Moxifloxacin.pdf
Size
1.35 MB
Format
Adobe PDF
Checksum (MD5)
a25c2f6760170ffad7f992f1883ff17e
Author(s)
Wang, Taejun
Jang, Won Hyuk
Lee, Seunghun
Yoon, Calvin J.
Lee, Jun Ho
Kim, Bumju
Hwang, Sekyu
Hong, Chun-Pyo
Yoon, Yeoreum
Lee, Gilgu
Date Issued
June 2016
Journal
Scientific Reports
Publisher
Springer Nature
Citation
Wang, Taejun, Won Hyuk Jang, Seunghun Lee, Calvin J. Yoon, Jun Ho Lee, Bumju Kim, Sekyu Hwang, et al. “Moxifloxacin: Clinically Compatible Contrast Agent for Multiphoton Imaging.” Scientific Reports 6 (June 10, 2016): 27142.
Version
Final published version
Abstract
Multiphoton microscopy (MPM) is a nonlinear fluorescence microscopic technique widely used for cellular imaging of thick tissues and live animals in biological studies. However, MPM application to human tissues is limited by weak endogenous fluorescence in tissue and cytotoxicity of exogenous probes. Herein, we describe the applications of moxifloxacin, an FDA-approved antibiotic, as a cell-labeling agent for MPM. Moxifloxacin has bright intrinsic multiphoton fluorescence, good tissue penetration and high intracellular concentration. MPM with moxifloxacin was demonstrated in various cell lines, and animal tissues of cornea, skin, small intestine and bladder. Clinical application is promising since imaging based on moxifloxacin labeling could be 10 times faster than imaging based on endogenous fluorescence.
MIT Department
Massachusetts Institute of Technology. Department of Biological Engineering
Massachusetts Institute of Technology. Department of Mechanical Engineering
Terms of Use
Creative Commons Attribution 4.0 International License
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1038/srep27142
